A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• Wee kinases regulate the DNA damage response by inhibiting the G2/M transition.
• Wee1 kinase is a key target in TP53-deficient cancers, with inhibitors like AZD-1775 in clinical trials.
• Toxicity and resistance necessitate novel therapeutic strategies, including protein degradation.

Purpose of the Study:

• To delineate the chemical space of the Wee1 binding pocket using chemoinformatics.
• To classify Wee1 inhibitors based on pocket engagement.
• To provide a framework for next-generation Wee1-directed drug design and translation.

Main Methods:

• Chemoinformatic analysis of Wee1 sequence and structure.
• Classification of inhibitors into three pocket engagement types.
• Construction of a high-resolution pocket map and an anchorable Markush structure.

Main Results:

• A detailed map of the Wee1 binding pocket chemical space was created.
• Inhibitors were classified based on their interaction with the Wee1 pocket.
• Design principles for Wee1 targeted degradation and synthetic lethality combination strategies were summarized.

Conclusions:

• The study provides an actionable framework for designing next-generation Wee1 inhibitors.
• Linking structural mechanisms to pharmacology and clinical data aids drug development.
• Biomarker-guided enrollment and dosing are crucial for clinical translation.